Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial

Moataz Maher Emara, Neamat Hamdy Elsawy, Kholoud M Abdelaaty, Amal Salah Elhamaky, Naglaa Hamdi Eltahan, Moataz Maher Emara, Neamat Hamdy Elsawy, Kholoud M Abdelaaty, Amal Salah Elhamaky, Naglaa Hamdi Eltahan

Abstract

Background: Although mass vaccination has reduced the severity of COVID-19, mortality is still high among hospitalized patients. Being a sepsis-like disease, an anti-inflammatory drug as atorvastatin would reduce mortality and severity in COVID-19.

Methods: We designed a randomized clinical trial that recruited 220 COVID-19 patients admitted in the COVID-19 isolation hospital at Mansoura University, Egypt. One hundred ten cases were assigned to receive 40 mg atorvastatin once daily for 28 days, and 110 were assigned to receive placebo. Delta Pharm company supported the study with the drug and the placebo, which mimics the drug as regards the drug package, the tablet color, consistency, and size. All patients received the standard treatment as per the hospital protocol. The Institutional Review Board approval and the informed consent from all participants were obtained. The primary outcome is the 28-day all-cause mortality. Additionally, we will collect the in-hospital mortality, the need for mechanical ventilation, time to clinical improvement, in-hospital thrombo-embolic events, acute kidney injury, and the hospital and the intensive care duration of stay. We plan to follow the patients up for 6 months for reporting mortality and long-term neurological, psychological, and respiratory consequences. We will report the un-adjusted 28-mortality using χ2. Then, we will report the adjusted odds ratio with a pre-planned multiple logistic regression model. We will report our results using the point estimate and the 95% confidence interval and the P-value.

Discussion: The additional issue that we would like to discuss is the added workload on the clinicians and the allied healthcare workers who performed research at the time of the pandemic. Therefore, doing research at the pandemic era was, indeed, challenging.

Trial registration: The study was registered at the Clinical Trial Registry ( NCT04952350 ) on July 1st, 2021.

Keywords: Atorvastatin; COVID-19; Coronavirus; Hmg coa; Mortality; Randomized controlled trial; SARS-CoV-2; Statins.

Conflict of interest statement

All authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments according to the SPIRIT template for the study timepoints
Fig. 2
Fig. 2
Interim analyses of the in-hospital mortality analyzed using χ2 at 25%, 50%, and 75% of patients, reporting the percent on the Y-axis and the number/total within the bars

References

    1. World Health Organization . COVID-19 weekly epidemiological update. 46 2021.
    1. Mondal S, Quintili AL, Karamchandani K, Bose S. Thromboembolic disease in COVID-19 patients: a brief narrative review. J Intensive Care. 2020;8:1–10. doi: 10.1186/s40560-020-00483-y.
    1. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1–4. doi: 10.3389/fimmu.2020.01446.
    1. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:1–7. doi: 10.1186/s41232-020-00146-3.
    1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z.
    1. Díez RR, Tejera-Muñoz A, Marquez-Exposito L, Mateos SR, Santos-Sanchez L, Marchant V, Tejedor-Santamaria L, Ramos A, Ortiz A, Egido J, Ruiz-Ortega M. Statins: could an old friend help the fight against COVID-19? Br J Pharmacol. 2020;177:4873–4886. doi: 10.1111/bph.15166.
    1. Lee KC, Sewa DW, Phua GC. Potential role of statins in COVID-19. Int J Infect Dis. 2020;96:615–617. doi: 10.1016/j.ijid.2020.05.115.
    1. Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. Eur Hear J Cardiovasc Pharmacother. 2020;6:410–411. doi: 10.1093/ehjcvp/pvaa055.
    1. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205:13–19. doi: 10.1093/infdis/jir695.
    1. Laidler MR, Thomas A, Baumbach J, Kirley PD, Meek J, Aragon D, Morin C, Ryan PA, Schaffner W, Zansky SM, Chaves SS. Statin treatment and mortality: propensity score-matched analyses of 2007–2008 and 2009–2010 laboratory-confirmed influenza hospitalizations. Open Forum Infect Dis. 2017;2:2633851.
    1. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691–698. doi: 10.1016/S2213-2600(18)30177-2.
    1. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32:176–187. doi: 10.1016/j.cmet.2020.06.015.
    1. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study. Crit Care. 2020;24:4–5. doi: 10.1186/s13054-020-03154-4.
    1. Lee JW, Choi EA, Kim YS, Kim Y, You HS, Han YE, et al. Statin exposure and the risk of dementia in individuals with hypercholesterolaemia. J Intern Med. 2020;288:689–698. doi: 10.1111/joim.13134.
    1. Kim SW, Kang HJ, Jhon M, Kim JW, Lee JY, Walker AJ, et al. Statins and inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry. 2019;10:103. doi: 10.3389/fpsyt.2019.00103.
    1. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. World Health Organization; 2021.
    1. Puri KS, Suresh KR, Gogtay NJ, Thatte UM. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009;55:131. doi: 10.4103/0022-3859.52846.
    1. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, Baillie K, Bauer M, Berry S, Blackwood B, Bonten M. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:192–197. doi: 10.1016/S1473-3099(20)30483-7.
    1. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138. doi: 10.1038/kisup.2012.1.
    1. Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á, Saravia-Bartra MM, Cazorla P, Belzusarri I, Hernandez AV. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. Int J Infect Dis. 2021;110:374–381. doi: 10.1016/j.ijid.2021.08.004.
    1. Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matching. J Clin Lipidol. 2021;15:451–459. doi: 10.1016/j.jacl.2021.03.002.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다